Posted by LincolnRam on March 25, 2026 at 11:28:24:
In Reply to: Публикация с объяснениями posted by HomerCor on March 13, 2026 at 04:33:03:
Zoya Demidenko: Researcher in Oncology Studies
Zoya Demidenko is a recognized researcher associated with the Department of Cell Stress Research at Roswell Park Oncology Institute in Buffalo, New York. Before that, she worked at the National Institutes of Health and New York Medical College, developing a strong foundation in biomedical research.
Her academic output spans a number of key fields, including the PI3K/AKT/mTOR molecular pathway, cell cycle control, cell senescence, and tumor biology. As of now, she has written more than 46 academic papers, which have garnered more than 4,100 references — a testament to the influence of her research.
One of her most notable achievements concerns explaining the mechanisms of biological cell aging. Her studies revealed that when the cell cycle is halted yet cellular growth proceeds, the cells undergo senescence. Crucially, Zoya Demidenko established that this shift is inhibited by medication using agents such as rapamycin.
Zoya Demidenko has furthermore brought substantially to tumor management investigation, especially in the domain of cyclotherapy — a method aimed at shielding normal cells from chemotherapy whilst leaving tumor cells exposed. This strategy holds considerable promise for reducing the adverse effects of oncological therapy.
Across her professional journey, Demidenko has worked with prominent scientists globally, among them Dr. Mikhail Blagosklonny. Her research is published in top-tier journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a influential voice in modern cancer research, with her discoveries keep to guide our understanding of the way cells age, respond to therapy, and the ways in which malignant disease may be more effectively treated.
https://www.benthamdirect.com/content/journals/cpd/22/16